» Articles » PMID: 25360548

P2Y6 Receptor Potentiates Pro-inflammatory Responses in Macrophages and Exhibits Differential Roles in Atherosclerotic Lesion Development

Abstract

Background: P2Y(6), a purinergic receptor for UDP, is enriched in atherosclerotic lesions and is implicated in pro-inflammatory responses of key vascular cell types and macrophages. Evidence for its involvement in atherogenesis, however, has been lacking. Here we use cell-based studies and three murine models of atherogenesis to evaluate the impact of P2Y(6) deficiency on atherosclerosis.

Methodology/principal Findings: Cell-based studies in 1321N1 astrocytoma cells, which lack functional P2Y(6) receptors, showed that exogenous expression of P2Y(6) induces a robust, receptor- and agonist-dependent secretion of inflammatory mediators IL-8, IL-6, MCP-1 and GRO1. P2Y(6)-mediated inflammatory responses were also observed, albeit to a lesser extent, in macrophages endogenously expressing P2Y(6) and in acute peritonitis models of inflammation. To evaluate the role of P2Y(6) in atherosclerotic lesion development, we used P2Y(6)-deficient mice in three mouse models of atherosclerosis. A 43% reduction in aortic arch plaque was observed in high fat-fed LDLR knockout mice lacking P2Y(6) receptors in bone marrow-derived cells. In contrast, no effect on lesion development was observed in fat-fed whole body P2Y(6)xLDLR double knockout mice. Interestingly, in a model of enhanced vascular inflammation using angiotensin II, P2Y(6) deficiency enhanced formation of aneurysms and exhibited a trend towards increased atherosclerosis in the aorta of LDLR knockout mice.

Conclusions: P2Y(6) receptor augments pro-inflammatory responses in macrophages and exhibits a pro-atherogenic role in hematopoietic cells. However, the overall impact of whole body P2Y(6) deficiency on atherosclerosis appears to be modest and could reflect additional roles of P2Y(6) in vascular disease pathophysiologies, such as aneurysm formation.

Citing Articles

Macrophage P2Y receptor signalling as a key mediator and therapeutic target in atherosclerosis.

Collado A, Zhou Z Purinergic Signal. 2025; .

PMID: 40072682 DOI: 10.1007/s11302-025-10083-w.


Ligand-Independent Spontaneous Activation of Purinergic P2Y Receptor Under Cell Culture Soft Substrate.

Nishimura A, Nishiyama K, Ito T, Mi X, Kato Y, Inoue A Cells. 2025; 14(3).

PMID: 39937007 PMC: 11817550. DOI: 10.3390/cells14030216.


Functionalized Congeners of 2-Chromene P2Y Receptor Antagonists.

Oliva P, Pramanik A, Jung Y, Lewicki S, Mwendwa J, Park J Cells. 2024; 13(16).

PMID: 39195256 PMC: 11352859. DOI: 10.3390/cells13161366.


Inflammation and cancer: friend or foe?.

Turizo-Smith A, Cordoba-Hernandez S, Mejia-Guarnizo L, Monroy-Camacho P, Rodriguez-Garcia J Front Pharmacol. 2024; 15:1385479.

PMID: 38799159 PMC: 11117078. DOI: 10.3389/fphar.2024.1385479.


Regulatory role of CD39 and CD73 in tumor immunity.

Kaplinsky N, Williams K, Watkins D, Adams M, Stanbery L, Nemunaitis J Future Oncol. 2024; 20(19):1367-1380.

PMID: 38652041 PMC: 11321403. DOI: 10.2217/fon-2023-0871.


References
1.
Gu L, Okada Y, Clinton S, Gerard C, Sukhova G, Libby P . Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell. 1998; 2(2):275-81. DOI: 10.1016/s1097-2765(00)80139-2. View

2.
Garcia R, Search D, Lupisella J, Ostrowski J, Guan B, Chen J . 11β-hydroxysteroid dehydrogenase type 1 gene knockout attenuates atherosclerosis and in vivo foam cell formation in hyperlipidemic apoE⁻/⁻ mice. PLoS One. 2013; 8(2):e53192. PMC: 3562192. DOI: 10.1371/journal.pone.0053192. View

3.
Guns P, Hendrickx J, Van Assche T, Fransen P, Bult H . P2Y receptors and atherosclerosis in apolipoprotein E-deficient mice. Br J Pharmacol. 2010; 159(2):326-36. PMC: 2825354. DOI: 10.1111/j.1476-5381.2009.00497.x. View

4.
Schiller N, Kubo N, Boisvert W, Curtiss L . Effect of gamma-irradiation and bone marrow transplantation on atherosclerosis in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol. 2001; 21(10):1674-80. DOI: 10.1161/hq1001.096724. View

5.
El-Tayeb A, Qi A, Muller C . Synthesis and structure-activity relationships of uracil nucleotide derivatives and analogues as agonists at human P2Y2, P2Y4, and P2Y6 receptors. J Med Chem. 2006; 49(24):7076-87. DOI: 10.1021/jm060848j. View